TCM in the Treatment of Lung Adenocarcinoma

Efficacy and Safety of Jing-yuan-kang Granule in the Treatment of Lung Adenocarcinoma

This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.

Study Overview

• Status: Unknown
• Conditions: Lung Adenocarcinoma
• Intervention / Treatment: Drug: Jing-yan-kang Granule; Drug: PC chemotherapy and symptomatic treatment

Detailed Description

Lung adenocarcinoma (LUAD) is a type of non-small cell lung cancer (NSCLC) with a rapid disease progression and poor treatment effect. The LUAD patients have a short median survival time with 8-11 months. Up to now, chemotherapy is still the first-line treatment for LUAD. PC protocol (pemetrexed + cisplatin) is most commonly used, which is also recommended by NCCN guidelines. However, critical side effects have limited the application and efficacy. Patients will undergo poor quality of life, and the disease will progress rapidly. We still face the stern situation for the treatment of LUAD. It is urgent to develop new treatment and management strategies. Our previous study showed that jing-yuan-kang granule has certain curative effect on LUAD.

This is a multi-certers, randomized, controlled clinical trial to assess the efficacy and safety of Jing-yuan-kang granule in improving quality of life for LUAD patients. After a 2-week wash-out period, a total of 144 LUAD patients will be randomly assigned into experimental or control group with a ratio of 1:1. On the basis of that all the participants will receive PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with no other treatments for control group. The primary outcome is quality of life. The secondary outcomes include Karnofsky (KPS) scores, clinical symptoms, and change of tumor volume. Safety and adverse events will also be assessed.

• Study Type: Interventional
• Enrollment (Anticipated): 144
• Phase: Not Applicable

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 71 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• A confirmed diagnosis of LADC.
• Age ranges from17years to75years.
• A KPS score ≥40.
• Without radiotherapy, immunotherapy and targeted therapy.
• Without participanting in any other trial.
• With signed informed consent.

Exclusion Criteria:

• Pregnant, nursing or may become pregnant women.
• The patient has a history of allergy to any of the components of the intervention drug;
• Patients with severe liver and kidney dysfunction, cardiovascular and cerebrovascular diseases.
• Unconscious or unable to communicate normally.
• Patients with poor compliance.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental Group; On the basis of PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with one dose daily.	Drug: Jing-yan-kang Granule; Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.; Drug: PC chemotherapy and symptomatic treatment; Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle. Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed. If necessary, symptomatic treatment will also be used.
Other: Control Group; All the patients in control group will receive PC chemotherapy and symptomatic treatment without other treatment.	Drug: PC chemotherapy and symptomatic treatment; Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle. Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed. If necessary, symptomatic treatment will also be used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The quality of life will be evaluated by The European Organization for Research and Treatment of Cancer Quality of life Questinnaire Core-30(EORTC QLQ-C30) scale	A score of 1-4 will be administrated for each item in EORTC QLQ-C30 . The higher scores will indicate the worse outcomes.	Change at 3 weeks, 6 weeks, 9 weeks, and 12 weeks after treatment compared to baseline.
Quality of life will be evaluated by Quality of life Questinnaire Lung Cancer-13(QLQ-LC13)	A score of 1-4 will be administrated for each item in QLQ-LC13. The higher scores will indicate the worse outcomes.	Change at 3 weeks, 6 weeks, 9 weeks, and 12 weeks after treatment compared to baseline.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Karnofsky(KPS) scores	Physical conditions will be evaluated by KPS scores with a score of 0-100. A higher score will indicate a better physical conditon.	Change at 3 weeks, 6 weeks, 9 weeks, and 12 weeks after treatment compared to baseline.
TCM syndrome index	TCM symptom index will be recorded and calculated referring to the Guiding Principles of Clinical Research of New Chinese Medicine Treating Primary Bronchial Lung Cancer (2002 Edition) published by National Medical Products Administration of China. A total of scores of all the related symptoms will be calculated with a 0-4 for each symptom at baseline and after treatment. A higher value will indicate a worse symptom. The difference of TCM symptoms between baseline and posttreatment will be calculated first. Then, we will obtain the TCM syndrome index by the ratio between the above difference and the scores at baseline.	Change at 3 weeks, 6 weeks, 9 weeks, and 12 weeks after treatment compared to baseline.
Change of tumor volume	Change of tumor volume will be assessed by the length of longest diameter. The longger diameter will indicate worse disease.	Change at 12 weeks after treatment compared to baseline.
Adverse events will be evaluated and recorded at any time.	Safety	at baseline, up to 6 weeks and 12 weeks after treatment.

Collaborators and Investigators

• Sponsor: Henan University of Traditional Chinese Medicine

Study record dates

Study Major Dates

• Study Start (Anticipated): September 15, 2020
• Primary Completion (Anticipated): December 30, 2020
• Study Completion (Anticipated): June 30, 2022

Study Registration Dates

• First Submitted: July 3, 2020
• First Submitted That Met QC Criteria: July 18, 2020
• First Posted (Actual): July 23, 2020

Study Record Updates

• Last Update Posted (Actual): July 23, 2020
• Last Update Submitted That Met QC Criteria: July 18, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Adenocarcinoma; Adenocarcinoma of Lung
• Other Study ID Numbers: TCM for lung adenocarcinoma

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No